SARS-CoV-2 Molecular Diagnostics Development
Explore our authenticated and clinically relevant materials for evaluating limit of detection, inclusivity, and cross-reactivity.
New Cancer Models
Check out our latest 3-D cancer models for glioblastoma, colon adenocarcinoma and cancer, and breast cancer.
Elevate your Toxicity Assays
Join our Talking Tox webinar at the ACT 2021 Annual Meeting to learn how hTERT-immortalized primary cells can provide effective tools for toxicology assays.
Clinical Diagnostics & Research
Join us at the Labroots Clinical Diagnostics & Research Virtual Event on November 10 to explore our resources for the development of diagnostic tools for infectious diseases and cancer.
SARS-CoV-2 Variant B.1.351
Now available – Genomic RNA prepared from SARS-CoV-2 strain USA/MD-HP01542/2021.
As the world works together to end the COVID-19 pandemic, ATCC is continuing its mission to provide the high-quality, authenticated material and data needed to create novel therapeutics, vaccines, and diagnostic tools. Through our accelerated efforts, we have expanded our portfolio to encompass a variety of resources to support your essential research, including heat-inactivated preparations, genomic and synthetic nucleic acids, polyclonal antibodies, microbial strains for cross-reactivity testing, and cell lines and supporting media for virus propagation. Explore our coronavirus resources today and be sure to explore the ATCC Genome Portal to access the whole-genome sequences of our SARS-CoV-2 strains.Find COVID-19 resources
ATCC Genome Portal
Enhanced Authentication Initiative
ATCC is not only enriching the characterization of our biological collections by using next-generation sequencing, we are also making those data available to everyone through the ATCC Genome Portal.
ATCC Genome Portal
The ATCC Genome Portal makes it easy to find the high-quality whole-genome sequencing data needed for your research. Using your ATCC login, you can easily search, download, and analyze hundreds of high quality genomes.
Advanced biological models
Amplify viral vaccine production
Antiviral vaccines are essential for preventing epidemic disease; however, the production of these therapeutics is often limited by low-yielding manufacturing processes. To address this, ATCC used cutting-edge CRISPR/Cas9 gene-editing technology to develop STAT1 knockout cell lines capable of producing high-titer viral stocks. These STAT1-KO cell lines are not only good candidates for enhancing virus titers for vaccine development, but also useful tools to package lentiviral, adenoviral, and retroviral vectors for the delivery of DNA sequences into target cells for various applications such as gene therapy and cancer immunotherapy.Find vaccine development resources
Discover next-generation organoid models
During the drug discovery process, having access to models that recapitulate tumor properties is essential for predictive screening. To meet this need, ATCC has made it a priority to provide patient-derived 3-D organoid models annotated with molecular and clinical data that represent a variety of healthy and cancerous tissues. These next-generation cancer models are capable of long-term expansion in culture while remaining phenotypically and genetically stable. Further, they provide invaluable preclinical models for studying cancer and offer many advantages over existing human or non-human animal cancer models.Explore patient-derived organoids
ATCC (American Type Culture Collection) is a nonprofit, global biological resource center and standards organization and the leading developer and supplier of authenticated cells lines and microorganisms. We leverage our rich history and knowledge to provide the products, services, and resources scientists need to conduct critical life science research.